

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

ANNOUNCEMENT

PROGRESS UPDATE ON THE PROPOSED ISSUE AND LISTING OF H SHARES OF FOSUN PHARMA ON THE HONG KONG STOCK EXCHANGE

Reference is made to the announcement of Fosun International Limited (the "**Company**") dated 28 February 2011 released at the website of The Stock Exchange of Hong Kong Limited ("**Hong Kong Stock Exchange**") in relation to the proposed issue and listing of H shares of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**"), a subsidiary of the Company and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196), on the Hong Kong Stock Exchange (the "**Proposed Global Offering**").

This announcement is made pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the "**Hong Kong Listing Rules**").

The board of directors (the "**Directors**") of the Company would like to update the shareholders of the Company and the public investors that a Web Proof Information Pack ("**WPIP**") of Fosun Pharma in relation to the Proposed Global Offering has been posted at the website of the Hong Kong Stock Exchange on 4 October 2012. The WPIP contains, among other things, the profit forecast of Fosun Pharma in draft form, extract of which is set out as below:

Fosun Pharma believes that on the bases and assumptions as set out in "Appendix III — Profit Forecast" to the WPIP and in the absence of unforeseen circumstances, Fosun Pharma's forecast consolidated profit attributable to owners of Fosun Pharma for the year ending 31 December 2012 is expected to be not less than RMB 1,490 million under the

Hong Kong Financial Reporting Standards. Fosun Pharma's forecast is based on the following key assumptions:

- The two subsidiaries Fosun Pharma acquired in the second half of 2011, namely Dalian Aleph Biomedical Company Limited (大連雅立峰生物製藥有限公司) and Jinzhou Aohong Pharmaceutical Company Limited (錦州奧鴻藥業有限責任公司), will make more contributions to Fosun Pharma's revenue and gross profits in 2012.
- Fosun Pharma's sales to Sinopharm Group Co. Ltd. ("**Sinopharm**") will increase in 2012 as Fosun Pharma further strengthens cooperation with Sinopharm.
- The percentage contribution of profits from Sinopharm will also increase in 2012 due to the continued growth of Sinopharm's business.
- Fosun Pharma will continue to derive a portion of Fosun Pharma's profit from gains from the disposal of available-for sale investments, the amount of which is forecasted based on disposals of Fosun Pharma's listed available-for sale investments at their lowest trading prices in the last five years.

Neither the Company nor any of the Directors shall be responsible for the accuracy or completeness of the information contained in the WPIP.

The Proposed Global Offering may or may not materialise, and, if it proceeds, it may constitute a notifiable transaction of the Company, and the Company will comply with the relevant requirements under the Hong Kong Listing Rules. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 4 October 2012

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Andrew Y. Yan, Mr. Zhang Huaqiao and Mr. David T. Zhang.